CA-FOCAL-SYSTEMS
16.3.2022 18:58:07 CET | Business Wire | Press release
On their mission to automate and optimize brick and mortar retail with state-of-the-art AI and deep learning, Focal Systems is proud to announce the launch of the world’s first “Self-Driving Store”-Operating System powered by computer vision and AI, called FocalOS. After 7 years hardening the platform with the largest retailers in the world, Focal's “Self-Driving Store”-Operating System is now Generally Available.
Enabled by AI-powered Shelf Cameras, FocalOS leverages computer vision and deep learning technology to provide real-time shelf digitization. This digitization feeds FocalOS, which automates order writing and ordering, directs stockers to double their productivity, optimizes category management on a per store basis, manages e-comm platforms to eliminate substitutions, tracks productivity per associate to drive further efficiencies, and much more. With FocalOS, corporate leaders can "teleport" into any store from anywhere in the world in seconds to see exactly what their shelves look like and how their stores are performing.
Major retailers have proven >50x ROI with FocalOS, making this the most profitable investment in all of retail technology.
Francois Chaubard, Founder and CEO, will unveil this solution in depth at the FMI Midwinter Conference in Orlando, Fla. on March 29.
Retailers have incredibly challenging jobs. Managing thousands of SKUs, employees, stores and ecommerce, while facing rising labor and supply chain costs and the evergreen battle for market share. Since 2015 our team has worked with leading global retailers to invent and implement AI solutions that drive true innovation, transformative financial returns and happy customers.
-Francois Chaubard - Founder/CEO Focal Systems
Focal has worked with leading retailers across North America, Europe and Australia and deployed more than 50,000 cameras worldwide. This launch enables retailers the ability to run fully automated “Self-Driving Stores" that achieve unprecedented labor efficiencies and sales growth just by setting the store on "Cruise Control" and letting the AI take it from there.
We’re always striving for more ways to improve the shopping experience for our customers. Focal is helping us use technology to improve our on-shelf customer availability, so our customers can find what they are looking for each time they choose to shop in-store with us.”
-Sam Wankowski - Chief Operations Officer, Walmart Canada
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state of the art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”-Operating System that revolutionizes how stores are run. Focal has raised more than $40m to date, and scaled their solutions to three continents and hundreds of stores, with thousands of cameras deployed. The Focal team is a carefully selected group of retail operations and AI experts who together have designed the next generation of operating systems for brick and mortar retail that leverages state-of-the-art AI and retail best practices to automate and optimize brick and mortar and on-line stores today.
Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom